Free Trial

Jane Wasman Purchases 20,000 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Stock

SELLAS Life Sciences Group logo with Medical background

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) Director Jane Wasman bought 20,000 shares of the firm's stock in a transaction on Friday, May 30th. The shares were acquired at an average cost of $1.69 per share, with a total value of $33,800.00. Following the purchase, the director now directly owns 30,400 shares of the company's stock, valued at approximately $51,376. This represents a 192.31% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.

SELLAS Life Sciences Group Stock Down 0.9%

Shares of NASDAQ SLS traded down $0.02 on Thursday, reaching $1.59. 275,418 shares of the company's stock traded hands, compared to its average volume of 1,553,475. SELLAS Life Sciences Group, Inc. has a 12 month low of $0.77 and a 12 month high of $2.12. The business's 50 day simple moving average is $1.45 and its two-hundred day simple moving average is $1.25. The company has a market cap of $158.15 million, a price-to-earnings ratio of -2.28 and a beta of 2.25.

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.11) by $0.04. Analysts forecast that SELLAS Life Sciences Group, Inc. will post -0.57 earnings per share for the current fiscal year.

Institutional Investors Weigh In On SELLAS Life Sciences Group

A number of institutional investors have recently made changes to their positions in the company. Opus Capital Group LLC grew its holdings in shares of SELLAS Life Sciences Group by 5.5% during the fourth quarter. Opus Capital Group LLC now owns 238,500 shares of the company's stock valued at $248,000 after buying an additional 12,400 shares during the last quarter. Virtu Financial LLC boosted its holdings in SELLAS Life Sciences Group by 30.9% in the first quarter. Virtu Financial LLC now owns 53,861 shares of the company's stock worth $58,000 after purchasing an additional 12,706 shares during the last quarter. Northern Trust Corp boosted its holdings in SELLAS Life Sciences Group by 33.6% in the fourth quarter. Northern Trust Corp now owns 134,721 shares of the company's stock worth $140,000 after purchasing an additional 33,878 shares during the last quarter. Geode Capital Management LLC boosted its holdings in SELLAS Life Sciences Group by 21.2% in the fourth quarter. Geode Capital Management LLC now owns 733,546 shares of the company's stock worth $763,000 after purchasing an additional 128,355 shares during the last quarter. Finally, Anson Funds Management LP boosted its holdings in SELLAS Life Sciences Group by 50.2% in the fourth quarter. Anson Funds Management LP now owns 1,192,266 shares of the company's stock worth $1,240,000 after purchasing an additional 398,431 shares during the last quarter. Hedge funds and other institutional investors own 17.38% of the company's stock.

SELLAS Life Sciences Group Company Profile

(Get Free Report)

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.

See Also

Should You Invest $1,000 in SELLAS Life Sciences Group Right Now?

Before you consider SELLAS Life Sciences Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SELLAS Life Sciences Group wasn't on the list.

While SELLAS Life Sciences Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Top 3 Defense Stocks to Profit From $175 Billion Golden Dome
Top 5 Stocks for June: AI Picks That Aren’t NVIDIA
This Unique Robotaxi Play Could Deliver 10X Returns

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines